Author | No. of Cases | Diagnosis | Drug | Dose | Age (yrs) | Gender | Presentation | RVSP | |||||
Younis, 2003 [26] | 1 | IgA (k), MM | Thal | 400 mg/d then reduced to 100 mg/d then to 50 mg/d | 51 | M | Peripheral edema | 70 mmHg (back to 47 mmHg after 2 months of Thal discontinuation) | |||||
Hattori et al., 2005 [27] | 1 | IgA (k), MM | Thal | 400 mg/d | 57 | F | Mild dyspnea on exertion | NA | |||||
Antonioli et al., 2005 [28] | 1 | IgG (k), MM | Thal | 100 mg/d with increase to 200 mg/d | 63 | M | Dizziness, asthenia and breathlessness | 90 mmHg (reduced to 60 mmHg after one month of Thal discontinuation) | |||||
Lafaras et al., 2008 [23] | 4 | IgG (λ), MM IgG (k), MM IgG (k), MM IgG (λ), MM | Thal | 200 mg/d | 59 68 72 76 | M F NA NA | Echocardiogram | 98 mmHg 54 mmHg NA NA | |||||
Villa et al., 2011 [29] | 1 | IgG (λ), MM | Thal | 50 mg/d | 79 | F | Asthenia, palpitation and dyspnea on exertion | 75 mmHg (reduced to 26 mmHg after one month of Thal discontinuation) | |||||
Tamura et al., 2014 [30] | 1 | Primary plasma cell leukemia (PPCL)* | L | 10 mg/d | 76 | M | Leg edema and dyspnea on exertion | Estimated mPAP 59 mmHg | |||||
Krishnan et al., 2015 [31] | 2 | IgA (k) MM IgA (k) MM | (L&P) Thal | NA | 72 69 | M F | Worsening dyspnea on exertion | 83 mmHg 65 mmHg | |||||